Clinical Trial Update: An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tenapanor for hyperphosphatemia in ESRD patients on hemodialysis has completed and posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphosphatemia

Drugs mentioned

• Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Hyperphosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2020-08-10